Short Interest in Mural Oncology plc (NASDAQ:MURA) Drops By 25.2%

Mural Oncology plc (NASDAQ:MURA) saw a significant decrease in short interest during the month of January. As of January 31st, there was short interest totalling 396,800 shares, a decrease of 25.2% from the January 15th total of 530,200 shares. Approximately 2.6% of the shares of the stock are sold short. Based on an average daily volume of 206,900 shares, the short-interest ratio is currently 1.9 days.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and set a $18.00 target price on shares of Mural Oncology in a report on Monday, November 11th.

Mural Oncology Trading Up 0.7 %

Shares of MURA traded up $0.03 during trading hours on Friday, hitting $4.29. 67,600 shares of the stock traded hands, compared to its average volume of 182,120. Mural Oncology has a 1-year low of $2.87 and a 1-year high of $5.62. The business has a fifty day moving average of $3.70 and a 200-day moving average of $3.52.

Hedge Funds Weigh In On Mural Oncology

Several large investors have recently made changes to their positions in MURA. Point72 Asset Management L.P. acquired a new position in shares of Mural Oncology during the third quarter valued at $340,000. Raymond James Financial Inc. acquired a new position in shares of Mural Oncology during the fourth quarter valued at $181,000. Virtu Financial LLC acquired a new position in shares of Mural Oncology during the fourth quarter valued at $129,000. Renaissance Technologies LLC lifted its stake in shares of Mural Oncology by 17.4% during the fourth quarter. Renaissance Technologies LLC now owns 238,465 shares of the company’s stock valued at $768,000 after acquiring an additional 35,403 shares during the period. Finally, Jane Street Group LLC acquired a new position in Mural Oncology in the fourth quarter valued at about $68,000. Institutional investors and hedge funds own 80.21% of the company’s stock.

About Mural Oncology

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.